Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab and lazertinib with platinum-pemetrexed versus platinum-pemetrexed after osimertinib failure in EGFR-mutated NSCLC
NL-OMON54075Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amivantamab, lazertinib, carboplatin and pemetrexed in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Started Aug 2022; status: recruiting.
02
Drugs
amivantamablazertinibcarboplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON54075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54075.